MDACC Study No:2008-0318 ( NCT No: NCT00895960)
Title:Phase I/II Trial of Dasatinib (Sprycel) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma
Principal Investigator:John DeGroot
Treatment Agent:Dasatinib; Temozolomide
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of dasatinib that can be given in combination with temozolomide. The safety of
this combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Dasatinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Bristol-Myers Squibb Company
Return Visit:Every 4 weeks
Home Care:Patients will take dasatinib and temozolomide at home

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults